Switch theme
Sign up to access all valuation multiples
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
2021
18
Last FY Revenue n/a
Last FY EBITDA -$13.1M
$250M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Tevogen Bio achieved revenue of n/a and an EBITDA of -$13.1M.
Tevogen Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tevogen Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$13.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$47.2M | XXX | -$53.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$23.8M | XXX | -$13.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tevogen Bio's stock price is $1.
Tevogen Bio has current market cap of $238M, and EV of $250M.
See Tevogen Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $250M | $238M | XXX | XXX | XXX | XXX | $-0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tevogen Bio has market cap of $238M and EV of $250M.
Tevogen Bio's trades at n/a EV/Revenue multiple, and -19.0x EV/EBITDA.
Equity research analysts estimate Tevogen Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tevogen Bio has a P/E ratio of -10.0x.
See valuation multiples for Tevogen Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $238M | XXX | $238M | XXX | XXX | XXX |
| EV (current) | $250M | XXX | $250M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -19.0x | XXX | XXX | XXX |
| EV/EBIT | -5.3x | XXX | -4.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.0x | XXX | -17.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -20.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTevogen Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.0M for the same period.
Tevogen Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tevogen Bio's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tevogen Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tevogen Bio acquired XXX companies to date.
Last acquisition by Tevogen Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Tevogen Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tevogen Bio founded? | Tevogen Bio was founded in 2021. |
| Where is Tevogen Bio headquartered? | Tevogen Bio is headquartered in United States of America. |
| How many employees does Tevogen Bio have? | As of today, Tevogen Bio has 18 employees. |
| Who is the CEO of Tevogen Bio? | Tevogen Bio's CEO is Dr. Ryan Saadi, M.D.,M.P.H.. |
| Is Tevogen Bio publicy listed? | Yes, Tevogen Bio is a public company listed on NAS. |
| What is the stock symbol of Tevogen Bio? | Tevogen Bio trades under TVGN ticker. |
| When did Tevogen Bio go public? | Tevogen Bio went public in 2024. |
| Who are competitors of Tevogen Bio? | Similar companies to Tevogen Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tevogen Bio? | Tevogen Bio's current market cap is $238M |
| Is Tevogen Bio profitable? | Yes, Tevogen Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
